Bacterial Vaginosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Bacterial Vaginosis – Pipeline Review, H2 2017’, provides an overview of the Bacterial Vaginosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis

The report reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bacterial Vaginosis therapeutics and enlists all their major and minor projects

The report assesses Bacterial Vaginosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bacterial Vaginosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Evofem Inc

Osel Inc

Starpharma Holdings Ltd

Symbiomix Therapeutics LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Vaginosis - Overview

Bacterial Vaginosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacterial Vaginosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Vaginosis - Companies Involved in Therapeutics Development

Evofem Inc

Osel Inc

Starpharma Holdings Ltd

Symbiomix Therapeutics LLC

Bacterial Vaginosis - Drug Profiles

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LACTIN-V - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

secnidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

subtilosin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Vaginosis - Dormant Projects

Bacterial Vaginosis - Discontinued Products

Bacterial Vaginosis - Product Development Milestones

Featured News & Press Releases

Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation

Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed

Mar 23, 2017: Symbiomix Therapeutics Announces FDA’s Acceptance of New Drug Application for Solosec with Priority Review Status

Feb 22, 2017: Symbiomix Therapeutics Appoints David L. Stern as Chief Executive Officer

Jan 19, 2017: Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec for the Treatment of BV

Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA

Nov 07, 2016: Symbiomix Therapeutics to Present Data on Solosec (Secnidazole) Oral Granules at 2016 AAPS Annual Meeting and Exposition

Oct 25, 2016: Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference

Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program

Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH

Aug 17, 2016: Symbiomix Therapeutics Accelerates Commercial Launch Preparation for Solosec Following Presentation of Results from Second Pivotal Trial at IDSOG

Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health

May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing

May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis

Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bacterial Vaginosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bacterial Vaginosis – Pipeline by Evofem Inc, H2 2017

Bacterial Vaginosis – Pipeline by Osel Inc, H2 2017

Bacterial Vaginosis – Pipeline by Starpharma Holdings Ltd, H2 2017

Bacterial Vaginosis – Pipeline by Symbiomix Therapeutics LLC, H2 2017

Bacterial Vaginosis – Dormant Projects, H2 2017

Bacterial Vaginosis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Bacterial Vaginosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports